← All storiesI · Deciding to challenge

Feature3 min readInter partes review

The inventors could challenge. The Director could refuse.

Assignor estoppel doesn’t bar an inter partes review: a 2013 Board decision, precedential as to § II.A only, and the Federal Circuit agree. In 2025 the Acting Director denied review anyway, where inventors who had assigned their rights were behind the petition. In 2026 the Federal Circuit declined to step in.

Allowed, then refusedTessell could file under the statute. The Acting Director still withdrew institution, and the court denied mandamus.

Before you read

Inventors who assigned a patent start a company, and it petitions for IPR. Can the Office refuse to hear it, even though assignor estoppel doesn’t apply?

Part 1 of 7

The founder’s company

Robert Schad was a named inventor on a Husky Injection Molding patent. He was also the founder, co-owner, president and CEO of Athena Automation, and one of its two directors. When Athena petitioned to cancel the patent’s claims, Husky made one argument: an inventor’s company shouldn’t be allowed to attack the inventor’s own patent. The Board instituted review of all 22 challenged claims.

Same inventor, different forums

Court or ITCIPR at the PTAB
Assignor estoppelCan limit validity attacks by an assignor and those in privityDoes not bar the petition (Athena; Arista)
WhyAn equitable doctrine; the ITC statute allows “[a]ll legal and equitable defenses”§ 311(a): “a person who is not the owner of a patent may file”
Discretion to refuseNot the questionYes: Tessell (2025)

Part 2 of 7

Start with the statute

Assignor estoppel is an equitable doctrine from the courts. Someone who assigns a patent, often an inventor assigning to an employer, generally can’t later argue in court that it is invalid. The Board began with the text instead: “a person who is not the owner of a patent may file with the Office a petition to institute an inter partes review.” An assignor, no longer the owner, is that person.

The Board contrasted the International Trade Commission, where the statute provides that “[a]ll legal and equitable defenses may be presented in all cases.” “Congress issued no similar statutory mandate to the Office in connection with AIA post-grant reviews.” And “none of Husky’s arguments addresses the language of § 311(a).”

“Congress issued no similar statutory mandate to the Office in connection with AIA post-grant reviews.”
Board, Athena Automation v. Husky Injection Molding, Oct. 25, 2013 (precedential as to § II.A only), contrasting the ITC statute

The Federal Circuit later agreed. In Arista v. Cisco, it held that the statute’s language leaves no place for assignor estoppel in IPR.

Part 3 of 7

Eligible, and refused

Tessell’s founders and employees included inventors who had assigned their rights to Nutanix. The Board instituted one of Tessell’s challenges; a related one had been denied. On August 22, 2025, the Acting Director vacated the institution and denied the petition.

Tessell v. Nutanix, in four steps

  1. 1BeforeThe assignmentInventors assign their rights to Nutanix.
  2. 2LaterThe new companyTessell’s founders and employees include those inventors. Tessell petitions.
  3. 3The BoardOne challenge institutedA related challenge had been denied.
  4. 4Aug 22, 2025The Acting DirectorAssignor estoppel doesn’t apply. Review is still inefficient here. Institution vacated; petition denied.
Step 1 of 4
The OfficeCourtThe turn

The order expressly acknowledged that assignor estoppel does not apply. It found review inefficient where the inventors now argued the claims were unpatentable. Tessell’s argument about broader claims in later patents of the family also lacked a sufficient comparison with the originally filed specification.

Part 4 of 7

No rescue on appeal

Tessell asked the Federal Circuit for mandamus, an extraordinary order directing the Office to act. On February 24, 2026, the court refused in a nonprecedential order.

The appeal plan

The tempting reading

If the Director refuses, the Federal Circuit will correct it under Arista.

Source

Part 5 of 7

Three questions, not one

For a company founded by or employing a patent’s inventors, the filing decision has three parts. A yes to the first doesn’t answer the other two.

Before an inventor-backed company files

May we file?Yes. Assignor estoppel doesn’t bar the petition (Athena, precedential as to § II.A only; Arista).
Will the Office choose to hear it?Not guaranteed. Tessell was denied on discretionary grounds.
What if it refuses?Review is limited. In re Tessell denied mandamus.

Part 6 of 7

What to do

Choose your side.

  • Map the inventors, assignments, employment changes and obligations before recommending an IPR.
  • If you argue the challenged claims differ from what the inventors assigned or originally disclosed, support it with an actual comparison to the original specification. Tessell’s comparison fell short.
  • Be ready to explain why review is a good use of Office resources despite the inventor connection.
  • Don’t budget on an appeal as the fallback. Mandamus failed in Tessell.

Part 7 of 7

Cuts the other way

The forum split cuts both ways. Because the ITC statute allows “[a]ll legal and equitable defenses,” an inventor’s company could face assignor estoppel at the ITC on the same patent it is free to challenge at the PTAB.

What these decisions show

They show

  • An assignor may file an IPR (Athena, precedential; Arista)
  • The Office may still decline, on discretionary grounds, to hear an inventor-backed petition (Tessell)
  • Mandamus is a narrow route back (In re Tessell)

They don’t show

  • That every company employing an inventor will be refused
  • A rule excluding inventors: Tessell is one Acting Director order, and the court’s order is nonprecedential
  • How often this happens

Athena has been precedential as to § II.A only since 2013, but it predates the current discretionary-denial practice, under which a petition can be eligible and still be refused. Tessell is one order, so how often inventor involvement leads to denial isn’t measured.

The takeaway

Assess the risk of refusal before budgeting for the merits, and before treating an appeal as the fallback.

Sources

  1. S27Athena Automation Ltd. v. Husky Injection Molding Sys. Ltd., No. IPR2013-00290, Paper 18 (P.T.A.B. October 25, 2013) (precedential as to § II.A only). Official source ↗
  2. S28Arista Networks, Inc. v. Cisco Systems, Inc., 908 F.3d 792 (Fed. Cir. 2018). Official source ↗
  3. S29Tessell, Inc. v. Nutanix, Inc., No. IPR2025-00298, Paper 17 (USPTO Acting Director Aug. 22, 2025). Official source ↗
  4. S30In re Tessell, Inc., No. 2026-117 (Fed. Cir. Feb. 24, 2026) (nonprecedential order). Official source ↗
  5. S13Federal patent statutes, 35 U.S.C. §§ 253(a), 303(a), 311–315, 317 and 321–325. Reproduced in MPEP Appendix L (currency date stated by the appendix: Jan. 31, 2024). Official page ↗

Precedential decisions bind the Board within their designated scope. Informative decisions show the Office’s reasoning but do not bind the Board. Court opinions are cited for what they decided; later history was checked on the date shown above.

Changes (5)
  • Replaced commentary with primary sources. The original flagged Tessell and In re Tessell as known only from blog posts; both are now cited from the official orders (Acting Director order, Aug. 22, 2025; Fed. Cir. order, Feb. 24, 2026), with facts from the reviewed note 13.
  • Added Arista v. Cisco (Fed. Cir. 2018), which holds that § 311(a) leaves no place for assignor estoppel in IPR. The original said this case law was not on hand.
  • Tessell corrected: the Board instituted one of Tessell’s challenges; a related one had been denied. The Acting Director vacated the institution and denied the petition.
  • Dropped the commentary’s “four of the patent’s inventors,” which was not checked against the order.
  • Headline taken from the reviewed note.
General information about published decisions, not legal advice. Reading it does not create an attorney-client relationship.
1 / 7